Compare AGCO Corporation (AGCO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGCO Corporation vs Recursion Pharmaceuticals Inc — how do they compare? AGCO Corporation trades at $102.25 (market cap $7.10B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B). The key difference: AGCO Corporation is far larger — about 3.9× Recursion Pharmaceuticals Inc's market cap, and AGCO Corporation pays a 1.18% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AGCO | RXRX | |
|---|---|---|
Market Cap | $7.10B | $1.81B |
Sector | Industrials | Health |
52-Week High | $140.49 | $6.79 |
52-Week Low | $100.14 | $2.84 |
Enterprise Value | $9.37B | $1.33B |
Dividend Yield | 1.18% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
